Legend Biotech Corporation
LEGN
Analyst Consensus
Price Objectif
Analyst historical
| Analyst | Entreprise | Price during analysis | Target price | Potential gain | Publication date |
|---|---|---|---|---|---|
| Ashwani Verma | UBS | 36.28 $ | 49 $ | 12.72 % | 03/06/2026 |
| Leonid Timashev | RBC Capital | 28.6401 $ | 64 $ | 35.36 % | 13/05/2026 |
| Terence Flynn | Morgan Stanley | 27.555 $ | 48 $ | 20.45 % | 13/05/2026 |
| Asthika Goonewardene | Truist Financial | 19.56 $ | 70 $ | 50.44 % | 10/03/2026 |
| Cui Cui | Jefferies | 19.56 $ | 69 $ | 49.44 % | 10/03/2026 |
| Qize Ding | Redburn Partners | 18.54 $ | 24 $ | 5.46 % | 12/02/2026 |
| Leonid Timashev | RBC Capital | 24.56 $ | 74 $ | 49.44 % | 08/12/2025 |
| Ashwani Verma | UBS | 28.13 $ | 48 $ | 19.87 % | 08/12/2025 |
| Ashwani Verma | UBS | 35.91 $ | 54 $ | 18.09 % | 02/07/2025 |
| Mitchell Kapoor | H.C. Wainwright | 37.19 $ | 75 $ | 37.81 % | 12/03/2025 |
| Rick Bienkowski | Cantor Fitzgerald | 55.9 $ | 83 $ | 27.10 % | 13/11/2024 |
| Justin Zelin | BTIG | 44.91 $ | 91 $ | 46.09 % | 15/10/2024 |
| Gena Wang | Johnson Rice | 45.245 $ | 94 $ | 48.76 % | 15/10/2024 |
| Gena Wang | Barclays | 44.91 $ | 94 $ | 49.09 % | 15/10/2024 |
| Qize Ding | Redburn Partners | 49.58 $ | 86 $ | 36.42 % | 08/10/2024 |
| Edward Tenthoff | Piper Sandler | 42 $ | 90 $ | 48.00 % | 17/06/2024 |
| Asthika Goonewardene | Truist Financial | 42.45 $ | 88 $ | 45.55 % | 17/06/2024 |
| James Shin | Deutsche Bank | 40.04 $ | 60 $ | 19.96 % | 23/05/2024 |
| Matthew Harrison | Morgan Stanley | 46.37 $ | 82 $ | 35.63 % | 17/05/2024 |
| Leonid Timashev | RBC Capital | 42.97 $ | 86 $ | 43.03 % | 14/05/2024 |
| George Farmer | Scotiabank | 50.12 $ | 65 $ | 14.88 % | 17/04/2024 |
| Rick Bienkowski | Cantor Fitzgerald | 56.43 $ | 82 $ | 25.57 % | 03/04/2024 |
| Kostas Biliouris | BMO Capital | 66.11 $ | 90 $ | 23.89 % | 14/03/2024 |